CareDx, Inc. (NASDAQ:CDNA - Get Free Report) CFO Keith Kennedy sold 2,097 shares of the business's stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $79.29, for a total transaction of $166,271.13. Following the sale, the chief financial officer owned 199,147 shares in the company, valued at $15,790,365.63. This trade represents a 1.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Keith Kennedy also recently made the following trade(s):
- On Thursday, November 5th, Keith Kennedy sold 61,961 shares of CareDx stock. The shares were sold at an average price of $77.82, for a total transaction of $4,821,805.02.
CareDx Trading Down 5.3%
CDNA traded down $4.16 on Monday, hitting $73.72. 1,030,751 shares of the company were exchanged, compared to its average volume of 981,669. CareDx, Inc. has a twelve month low of $15.15 and a twelve month high of $90.87. The company has a market cap of $3.87 billion, a price-to-earnings ratio of 30.85 and a beta of 2.50. The firm has a 50-day moving average price of $66.34 and a two-hundred day moving average price of $36.70.
CareDx (NASDAQ:CDNA - Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.45. CareDx had a net margin of 25.86% and a return on equity of 9.74%. The firm had revenue of $139.36 million for the quarter, compared to analysts' expectations of $121.96 million. During the same quarter last year, the company earned $0.03 earnings per share. The firm's revenue was up 39.3% compared to the same quarter last year. Equities analysts expect that CareDx, Inc. will post 1.00 EPS for the current year.
Institutional Trading of CareDx
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CDNA. BlackRock Inc. purchased a new stake in shares of CareDx during the 2nd quarter worth approximately $137,219,000. Bamco Inc. NY acquired a new position in shares of CareDx in the 2nd quarter valued at $55,214,000. Amova Asset Management Americas Inc. grew its position in shares of CareDx by 2.0% in the 1st quarter. Amova Asset Management Americas Inc. now owns 1,475,126 shares of the company's stock valued at $25,608,000 after buying an additional 28,510 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of CareDx by 11.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,461,914 shares of the company's stock valued at $25,375,000 after buying an additional 151,934 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in CareDx by 7.2% during the 1st quarter. Renaissance Technologies LLC now owns 1,184,398 shares of the company's stock worth $20,561,000 after acquiring an additional 79,200 shares in the last quarter.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on CDNA shares. Wall Street Zen lowered shares of CareDx from a "strong-buy" rating to a "buy" rating in a report on Saturday, October 31st. BTIG Research boosted their target price on shares of CareDx from $81.00 to $92.00 and gave the stock a "buy" rating in a research note on Friday, October 30th. Piper Sandler assumed coverage on CareDx in a research note on Wednesday, November 11th. They issued an "overweight" rating and a $100.00 price target on the stock. Weiss Ratings upgraded CareDx from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, October 8th. Finally, Canaccord Genuity Group set a $99.00 price target on CareDx in a report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $70.33.
Read Our Latest Research Report on CareDx
About CareDx
(
Get Free Report)
CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.